Balyasny Asset Management’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-29,524
Closed -$23K 3397
2022
Q2
$23K Buy
+29,524
New +$26K ﹤0.01% 2463
2022
Q1
Sell
-15,597
Closed -$20K 2993
2021
Q4
$20K Buy
+15,597
New +$27.9K ﹤0.01% 2150
2020
Q4
Sell
-34,252
Closed -$140K 1808
2020
Q3
$140K Buy
+34,252
New +$130K ﹤0.01% 1225
2019
Q3
Sell
-105,556
Closed -$909K 1705
2019
Q2
$909K Buy
105,556
+53,842
+104% +$482K 0.01% 1106
2019
Q1
$553K Sell
51,714
-257,783
-83% -$2.76M ﹤0.01% 1181
2018
Q4
$2.71M Buy
+309,497
New +$3.94M 0.02% 637
2018
Q3
Sell
-335,028
Closed -$7.25M 2138
2018
Q2
$7.02M Sell
335,028
-48,395
-13% -$896K 0.03% 585
2018
Q1
$6.17M Sell
383,423
-177,495
-32% -$3.52M 0.03% 649
2017
Q4
$10.6M Buy
+560,918
New +$10.2M 0.03% 617
2016
Q1
Sell
-12,608
Closed -$76K 1589
2015
Q4
$76K Buy
+12,608
New +$72.1K ﹤0.01% 1177
2013
Q4
Sell
-373,336
Closed -$3.13M 675
2013
Q3
$3.13M Buy
373,336
+223,336
+149% +$1.81M 0.04% 416
2013
Q2
$1.12M Buy
+150,000
New +$1.15M 0.02% 480

Other funds holding SPPI

Balyasny Asset Management's SPPI Position: Q3 2022 in Review

Balyasny Asset Management sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q3 2022, closing a stake of 29,524 shares — an estimated $23K sold.

Balyasny Asset Management first reported a position in SPPI in Q2 2013 and held it in 12 quarters. The position peaked at $10.6M in Q4 2017. 75 funds tracked by Wall St. Rank hold SPPI as of Q3 2022.

  • Balyasny Asset Management reported no remaining Spectrum Pharmaceuticals Inc position as of Q3 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 29,524 Spectrum Pharmaceuticals Inc shares in Q3 2022, an estimated $23K.
  • Balyasny Asset Management first reported a position in Spectrum Pharmaceuticals Inc in Q2 2013 and held it in 12 quarters.
  • Balyasny Asset Management's Spectrum Pharmaceuticals Inc position peaked at $10.6M in Q4 2017.
  • 75 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q3 2022.

Based on Balyasny Asset Management's 13F filing for Q3 2022, filed 15 Nov 2022.